EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis

Margarita Panova, Maria Spasova, Snezhana Stoencheva, Teodora Dimcheva iD, Iglika Sotkova-Ivanova, Pamela Boykova

Children · 08.06.2026 · 13 (6) · 792

DOI: 10.3390/children13060792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Children, online erschienen am 08.06.2026. Verfasst von Margarita Panova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics "Prof. Dr. Ivan Andreev", Medical University Plovdiv, 4002 Plovdiv, Bulgaria. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University Plovdiv.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of low-molecular-weight heparins (LMWH) for the treatment and prevention of thromboembolic diseases in pediatric patients is increasing, although optimal dosing and monitoring strategies remain insufficiently defined.

Methods

This study was conducted at the Clinic of Pediatrics, University Hospital “St. George”, and included 26 hospitalized patients aged 0–18 years with confirmed arterial or venous thrombosis receiving treatment or prophylaxis with enoxaparin. A total of 42 samples were analyzed. Anti-factor Xa activity was measured using an LMWH-calibrated anti-FXa assay (Innovance Heparin, Siemens Healthineers) on a Sysmex CS-2500 analyzer. Therapeutic and prophylactic dosing followed CHEST 2012 guidelines. The study evaluated age- and weight-based dosing, the number of dose adjustments required to achieve target Anti-Xa levels, and the relationship between Anti-Xa levels and anticoagulant response.

Results

The mean baseline Anti-Xa level achieved with the initial weight-based dose (1.0 mg/kg/12 h) was significantly lower in children aged 1–2 years compared with older age groups. Older children, as well as patients with oncological and nephrological diseases, achieved higher anticoagulant levels with standard prophylactic dosing. Age under 1 year, oncological disease, and baseline Anti-Xa level < 0.3 IU/mL were identified as independent predictors of the need for more frequent dose adjustments to achieve a therapeutic response.

Conclusions

Monitoring of Anti-factor Xa levels is essential in pediatric patients receiving LMWH for both treatment and prophylaxis. Standard dosing regimens may be insufficient in younger children and specific clinical subgroups, supporting the need for individualized dosing strategies.

Schlagwörter

Stichwörter der Autor:innen

anti-factor Xaanticoagulationenoxaparinlow-molecular-weight heparinmonitoringpediatric thrombosis

Autor:innen und Institutionen

  • Department of Pediatrics "Prof. Dr. Ivan Andreev", Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
  • Department of Clinical Laboratory, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
  • Department of Medical Informatics, Biostatistics and E-Learning, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.
  • Department of Medical Genetics, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.

ORCID-Profile: Teodora Dimcheva

Förderung

  • Medical University Plovdiv

Zitieren

APA

Panova, M., Spasova, M., Stoencheva, S., Dimcheva, T., Sotkova-Ivanova, I., & Boykova, P. (2026). Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis. Children, 13(6), 792. https://doi.org/10.3390/children13060792

Vancouver

Panova M, Spasova M, Stoencheva S, Dimcheva T, Sotkova-Ivanova I, Boykova P. Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis. Children. 2026;13(6):792. doi:10.3390/children13060792

BibTeX
@article{Panova2026,
  author = {Panova, Margarita and Spasova, Maria and Stoencheva, Snezhana and Dimcheva, Teodora and Sotkova-Ivanova, Iglika and Boykova, Pamela},
  title = {Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis},
  journal = {Children},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {792},
  doi = {10.3390/children13060792}
}
Kostenlos starten →